Versanis Bio
Versanis is dedicated to developing transformative treatments for obesity and cardiometabolic diseases by combining deep understanding of activin biology with Lilly's expertise in incretin biology. Their approach targets activin type II receptors to regulate fat and muscle metabolism, aiming to improve body composition and metabolic health in people living with obesity.
Industries
Nr. of Employees
small (1-50)
Versanis Bio
Oakland, California, United States, North America
Products
Research programs targeting activin type II receptors for obesity and cardiometabolic diseases
Preclinical and translational research programs focused on blocking activin signaling via activin type II receptors to alter body composition (increase muscle, reduce fat) and to address activin-mediated cardiac damage.
Research programs targeting activin type II receptors for obesity and cardiometabolic diseases
Preclinical and translational research programs focused on blocking activin signaling via activin type II receptors to alter body composition (increase muscle, reduce fat) and to address activin-mediated cardiac damage.
Services
Clinical trial participant information
Provides online participant-facing information and privacy statement for individuals involved in clinical trials related to the company's research programs.
Clinical trial participant information
Provides online participant-facing information and privacy statement for individuals involved in clinical trials related to the company's research programs.
Expertise Areas
- Obesity therapeutics development
- Cardiometabolic disease research
- Activin pathway biology
- Muscle and adipose tissue biology
Key Technologies
- Activin type II receptor modulation
- Incretin pathway modulation
- Pathway-based therapeutic discovery
- Translational genetic target identification